First-pass extracted concept

optogenetic therapy

Candidate: concept label2 source documents5 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

The abstract describes optogenetic therapy as a genomic approach being tested clinically to restore vision in blind people with degenerative eye disease.

Source 1DOI PubMed

Resources required

It requires light stimulation and targeting of appropriate cell types, as implied by the discussion of required light levels and cell-type targeting strategies.

Source 1DOI PubMed

What problem it solves

It aims to restore visual function after degenerative loss of native photoreceptor function.

Source 1DOI PubMed

What it does not solve

The abstract states that achieved visual acuity and whether it reaches the theoretical limit remain unresolved.

Source 1DOI PubMed

Alternatives

The paper contrasts optogenetic therapy with proposed sonogenetic therapy using ultrasound and mechanosensitive channels.

Source 1DOI PubMed

Evidence Snippets

optogenetic therapy has entered successfully in clinical trials for restoring vision to blind people with degenerative eye diseases

Evidence 1Source 1DOI PubMedprovenance

downstream retinal neurons, which can be targeted for optogenetic therapy

Evidence 2Source 2DOI PubMedprovenance

Supporting Sources

Source 1primary paper2022MEDDOI PubMed

1 evidence snippet 5 linked claims Claim 1 Claim 2 Claim 3

Source 2primary paper2019Nature CommunicationsDOI PubMed

1 evidence snippet 0 linked claims

Linked Claims

Claim 1clinical translation statussupports2022Source 1DOI PubMed

Optogenetic therapy has successfully entered clinical trials for restoring vision in blind people with degenerative eye diseases such as retinitis pigmentosa.

Quoted textsource-backed

optogenetic therapy has entered successfully in clinical trials for restoring vision to blind people with degenerative eye diseases, such as retinitis pigmentosa

Claim 2engineering strategysupports2022Source 1DOI PubMed

Parallel optogenetic strategies aim to reduce required light levels and improve information processing by targeting different cell types.

Quoted textsource-backed

Different strategies are developed in parallel to reduce required light levels and improve information processing by targeting various cell types.

Claim 3future applicationsupports2022Source 1DOI PubMed

Genomic approaches may provide efficient brain-machine interfaces for sight restoration.

Quoted textsource-backed

Genomic approaches may thus provide efficient brain machine interfaces for sight restoration.

Claim 4limitationsupports2022Source 1DOI PubMed

Current clinical trials of optogenetic therapy still need to determine the visual acuity achieved by patients and whether it reaches the theoretical limit extrapolated from ex vivo experiments.

Quoted textsource-backed

These clinical trials still have to evaluate the visual acuity achieved by patients and to determine if it reaches its theoretical limit extrapolated from ex vivo experiments.

Claim 5limitationsupports2022Source 1DOI PubMed

Optogenetic cortical stimulation for vision loss due to optic atrophy is hampered by light absorption and scattering in brain tissue.

Quoted textsource-backed

For patients with vision loss due to optic atrophy, as in the case of glaucoma, optogenetic cortical stimulation is hampered by light absorption and scattering by the brain tissue.